Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe

Ozaras, R. and Corti, G. and Ruta, S. and Lacombe, K. and Mondelli, M. U. and Irwing, W. L. and Puoti, M. and Khalighi, A. and Santos, M. L. and Harxhi, A. and Lazarevic, I. and Soriano, V. and Gervain, J. and Leblebicioglu, H. and Salmon, D. and Arends, J. E. and The, Escmid Study Group for Viral Hepatitis (2015) Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. Clinical Microbiology and Infection, 21 (11). pp. 1027-1032.

[img] Text
1-s2.0-S1743919114009960-main.pdf

Download (1MB)

Abstract

The prevalence and management of chronic hepatitis B virus (HBV) infection differ among European countries. The availability and reimbursement of diagnostics and drugs may also vary, determining distinct treatment outcomes. Herein, we analyse differences in medical facilities for the care of patients with chronic HBV infection across Europe. A survey was sent to the members of the ESCMID Study Group for Viral Hepatitis, all of whom are experts in chronic HBV infection management. The comprehensive survey asked questions regarding hepatitis B surface antigen (HBsAg) prevalence, the availability of diagnostics and drugs marketed, and distinct clinical practice behaviours in the management of chronic HBV infection. World Bank data were used to assess the economic status of the countries. With 16 expert physicians responding (69), the HBsAg prevalence rates were <1 in France, Hungary, Italy, The Netherlands, Portugal, Spain, and the UK, intermediate (1-5) in Turkey, Romania, and Serbia, and high (>5) in Albania and Iran. Regarding the availability and reimbursement of HBV diagnostics (HBV DNA and liver stiffness measurement), HBV drugs (interferon, lamivudine, tenofovir, and entecavir), HBV prophylaxis, and duration of HBeAg-positive and HBeAg-negative HBV infection, the majority of high-income and middle-income countries had no restrictions; Albania, Iran and Serbia had several restrictions in diagnostics and HBV drugs. The countries in the high-income group were also the ones with no restrictions in medical facilities, whereas the upper-middle-income countries had some restrictions. The prevalence of chronic HBV infection is much higher in southern and eastern than in western European countries. Despite the availability of European guidelines, policies for diagnostics and treatment vary significantly across European countries. © 2015 European Society of Clinical Microbiology and Infectious Diseases.

Item Type: Article
Additional Information: Cited By :4 Export Date: 16 February 2020 CODEN: CMINF Correspondence Address: Ozaras, R.; Infection Department, Istanbul University Cerrahpasa Medical SchoolTurkey; email: rozaras@yahoo.com
Uncontrolled Keywords: Chronic hepatitis B Diagnostic Prevalence Treatment Viral hepatitis alanine aminotransferase antivirus agent entecavir hepatitis B surface antigen hepatitis B(e) antigen lamivudine peginterferon alpha tenofovir disoproxil virus DNA Albania antiviral therapy Article drug marketing elastography follow up France health care availability health care survey human Hungary immunotherapy income infection prevention Iran Italy major clinical study molecular diagnosis Netherlands Portugal priority journal reimbursement Romania Serbia serodiagnosis Spain Turkey (republic) United Kingdom university hospital blood diagnostic test drug utilization Europe female health care delivery Hepatitis B, Chronic male procedures questionnaire utilization Antiviral Agents Diagnostic Tests, Routine Health Services Accessibility Hepatitis B Surface Antigens Humans Seroepidemiologic Studies Surveys and Questionnaires
Subjects: WI Digestive System
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib5 lib5
Date Deposited: 04 May 2020 07:33
Last Modified: 04 May 2020 07:33
URI: http://eprints.mums.ac.ir/id/eprint/19025

Actions (login required)

View Item View Item